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INTRODUCTION 
Praziquantel (PZQ) is the antihelmintic drug of first choice 
against Schistosomiasis, an infectious diseases affecting at 
least 230 million people worldwide.1 This drug is of low 
cost, highly efficient with little side effects, but it has, 
although, low solubility and extensive first-pass 
metabolism,2 causing high dosages often difficult to 
swallow in children, the main target of this treatment. This 
study reports the only ever-known polymorph of PZQ, 
Form B, obtained by grinding in a vibrational mill. 
Considering different polymorphs of a drug, significant 
differences can be noticed, not only in the crystalline 
structure and arrangements at the solid state (which 
represent the necessary conditions of being) but more 
interestingly in the physical, chemical and 
biopharmaceutical properties.3 Actually the known crystal 
structure of PZQ in the CSD are represented by the 
anhydrous commercial racemic compound (TELCEU), the 
enantiomeric hemihydrates (SIGBUG and SIGBUG01) 
some derivatives and cocrystal with dicarboxylic acids.4 
PZQ crystallization by slow evaporation in different 
solvents is reported to lead to the same raw drug.5 In this 
study the crystalline structure of Form B was solved from 
the powder X-ray diffraction pattern (CSD dep. n. 1557658) 
then fully characterized both at the solid state and in its 
biopharmaceutical properties (i.e. saturation solubility and 
intrinsic dissolution rate) comparing to raw PZQ. Finally, 
the antihelmintic activity both in vitro and in vivo (in mice) 
was tested. 
MATERIALS  
Praziquantel Ph. Eur. Grade (Fatro S.pA., Bologna, Italy); 
HiPersolv Chromanorm Methanol, Ph. Eur. for HPLC 
Gradient Grade (VWR Chemicals BHD PROLABO®).  
METHODS 
Form B preparation 
PZQ Form B was prepared via neat grinding of raw PZQ in 
a Retsch MM400 (Retsch GmbH) vibrational mill, using 2 
screw-type zirconium oxide jars of 35 ml and 3 zirconium 
oxide balls (Ø=15 mm). 
Form B characterization 
The solid state of PZQ Form B was fully characterized by 
DSC, TGA, polarimetry, ATR-IR, FT-IR (KBr), Scanning 
Electron Microscopy (SEM), SS-NMR and powder X-ray 
diffraction using conventional and synchrotron sources. For 
the determination of the drug content a Shimadzu reversed-
phase HPLC-UV was used, with a mobile phase of 
methanol:water (65:35 V/V). The water solubility was 
tested at 20 °C while and the intrinsic dissolution rate at 37 
°C, using in both cases the same HPLC-UV system for drug 
quantification. Finally, the activity of Form B was 
evaluated both in vitro and in vivo (in mice) against S. 
mansoni. 
RESULTS AND DISCUSSION 
PZQ Form B is the only ever-known anhydrous polymorph 
of PZQ: its PXRD pattern was clearly different form raw 
PZQ since the characteristic peak at 4 of 2θ disappeared 
while two intense peak at 6.9 and 8.5 of 2θ were evidenced. 
The solution of the new phase from the powder X-ray 
diffraction pattern revealed the presence of one molecule in 
the asymmetric unit, in a monoclinic space group C2/c (see 
Figure 1). Conversely, raw PZQ has a triclinic unit cell (P-
1) where 4 crystallographically independent molecules are 
arranged, of which 2 are disordered.4 The crystal habit of 
Form B observed by SEM revealed an agglomeration of 
whiskers, different from the acicular shape of raw PZQ. 
The anhydrous nature of Form B was confirmed by DSC 
and TGA, with a single event at 112 °C corresponding to 
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the melting of the polymorph. A similar melting point and 
crystal space group was reported for the enantiomeric 
hemihydrate of PZQ, but the polarimetric analysis of Form 
B showed no enantiomeric excess. The total amount of 
impurity, analyzed by HPLC, resulted in less than 1%. 
 
Figure 1. Praziquantel Form B unit cell (C2/c). 
The SSNMR (13C and 15N) confirmed the novelty and 
crystallinity of Form B and also the presence of one 
independent molecule in the unit cell, since a single set of 
resonances in 13C was evidenced. The ATR-IR spectra of 
Form B comparing to raw PZQ evidenced again the 
difference between the two phases, particularly in the 
carbonyl stretching range. The high resolution FT-IR 
permitted to highlight also a different crystal conformation 
of the two phases: in fact the C=O groups in raw PZQ are in 
the syn conformation, while in Form B the anti 
conformation gives origin to a closer double peak (1642-
1632 cm-1)  than the one of PZQ (1653-1628 cm-1). The 
biopharmaceutical properties of the new form were 
analyzed and compared to raw PZQ. The solubility in water 
of the new phase at 20 °C (after 48h under stirring in the 
dark) was double than raw PZQ with a value of 281.31 
mg/L comparing to 140.30 mg/L. The intrinsic dissolution 
rate (37 °C) followed the same trend with a value of 0.062 
± 0.0042 mg*cm-2/min for Form B and of 0.0312 ± 0.003 
for raw PZQ (see Figure 2). 
 
Figure 2. Water solubility and intrinsic dissolution rate of PZQ 
and Form B. 
The in vitro and in vivo activity of Form B against S. 
mansoni was maintained and enhanced, comparing to raw 
PZQ, as showed in Table 1. Finally, the new phase showed 
to be physically stable (by PXRD and DSC) for more than 
one year. 
Sample 
In vitro IC50 
(72h) 
Qg/ml 
In vivo (mice) %  
Schistsomule 
reduction after 49 
days treatment   
PZQ 165 96.8 
Form B 135 100.0 
Table 1. In vitro and in vivo activity of PZQ and Form B 
against S. Mansoni. 
CONCLUSIONS 
This work reports the only ever-known polymorph of PZQ 
(Form B), obtained through a mechanochemical process in 
a vibrational mill. This new phase, after being fully 
characterized at the solid state, was evaluated not only in its 
biopharmaceutical properties, but also in its activity both in 
vitro and in vivo against S. mansoni. Form B has a double 
solubility and intrinsic dissolution rate in water than raw 
PZQ, slightly enhancing the antischistosomal activity. 
These interesting properties of Form B, together with its 
stability for more than one year make this new form an 
interesting product for the design of new PZQ formulations. 
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